DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 173 filers reported holding DENALI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,015,144 | -41.8% | 34,400 | -54.6% | 0.00% | -40.0% |
| Q1 2023 | $1,745,073 | -15.7% | 75,741 | +1.8% | 0.01% | -16.7% |
| Q4 2022 | $2,070,037 | -74.2% | 74,435 | -71.5% | 0.01% | -77.8% |
| Q3 2022 | $8,015,000 | +323.4% | 261,170 | +306.0% | 0.03% | +350.0% |
| Q2 2022 | $1,893,000 | +96.2% | 64,324 | +114.4% | 0.01% | +100.0% |
| Q1 2022 | $965,000 | +152.6% | 30,001 | +249.8% | 0.00% | +200.0% |
| Q4 2021 | $382,000 | -93.3% | 8,576 | -92.5% | 0.00% | -92.3% |
| Q3 2021 | $5,735,000 | -66.7% | 113,671 | -48.2% | 0.01% | -66.7% |
| Q2 2021 | $17,211,000 | -39.3% | 219,415 | -55.8% | 0.04% | -47.3% |
| Q1 2021 | $28,362,000 | +29.7% | 496,703 | +90.3% | 0.07% | +17.5% |
| Q4 2020 | $21,867,000 | +219.5% | 261,070 | +36.7% | 0.06% | +162.5% |
| Q3 2020 | $6,845,000 | +125.5% | 191,045 | +52.2% | 0.02% | +60.0% |
| Q2 2020 | $3,036,000 | – | 125,538 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |